TW200720656A - Prediction of prognosis of liver disease associated with hepatitis c virus infection - Google Patents

Prediction of prognosis of liver disease associated with hepatitis c virus infection

Info

Publication number
TW200720656A
TW200720656A TW095114055A TW95114055A TW200720656A TW 200720656 A TW200720656 A TW 200720656A TW 095114055 A TW095114055 A TW 095114055A TW 95114055 A TW95114055 A TW 95114055A TW 200720656 A TW200720656 A TW 200720656A
Authority
TW
Taiwan
Prior art keywords
hepatitis
amino acid
peptide
prediction
liver disease
Prior art date
Application number
TW095114055A
Other languages
Chinese (zh)
Inventor
Kyogo Itoh
Michio Sata
Shigeru Yutani
Nobukazu Komatsu
Akira Yamada
Original Assignee
Univ Kurume
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kurume filed Critical Univ Kurume
Publication of TW200720656A publication Critical patent/TW200720656A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Disclosed is a method for the prediction of progress of a liver disease associated with HCV infection, the method comprising determining the antibody titer of an antibody against a peptide comprising an amino acid sequence composed of contiguous 8 or more amino acid residues containing amino acid Gly 32 of a hepatitis C virus core protein in the blood of a subject. Further, the antibody titer against NS5A-2132 peptide of hepatitis C virus and the antibody titer against C33 or C35 peptide of a hepatitis C virus core protein are also determined. Based on the combination of these results, it becomes possible to predict the prognosis with higher reliability. Also disclosed is a kit for use in the prediction of the progress of a liver disease associated with hepatitis C virus infection, the kit comprising a peptide which can be recognized by an anti-HCV antibody capable of binding to a peptide comprising an amino acid sequence composed of contiguous 8 or more amino acid residues containing amino acid Gly 32 of a hepatitis C virus core protein.
TW095114055A 2005-04-19 2006-04-19 Prediction of prognosis of liver disease associated with hepatitis c virus infection TW200720656A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005121293 2005-04-19

Publications (1)

Publication Number Publication Date
TW200720656A true TW200720656A (en) 2007-06-01

Family

ID=37115194

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095114055A TW200720656A (en) 2005-04-19 2006-04-19 Prediction of prognosis of liver disease associated with hepatitis c virus infection

Country Status (3)

Country Link
JP (1) JP4615567B2 (en)
TW (1) TW200720656A (en)
WO (1) WO2006112482A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004285019B9 (en) 2003-10-27 2011-11-24 Vertex Pharmaceuticals Incorporated HCV NS3-NS4A protease resistance mutants
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
EP2392590A3 (en) * 2005-11-11 2012-03-14 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
WO2010050181A1 (en) * 2008-10-27 2010-05-06 株式会社グリーンペプタイド Vaccine for preventing onset and recurrence of liver cancer induced by hepatitis c virus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3055793B2 (en) * 1990-09-07 2000-06-26 財団法人化学及血清療法研究所 Non-A non-B hepatitis virus fusion peptide and method for producing the same
DE4240980A1 (en) * 1992-08-07 1994-02-10 Boehringer Mannheim Gmbh HCV peptide antigens and method for the determination of HCV
WO2005028503A1 (en) * 2003-09-22 2005-03-31 Green Peptide Co., Ltd. Peptide originating in hepatitis c virus

Also Published As

Publication number Publication date
WO2006112482A1 (en) 2006-10-26
JP4615567B2 (en) 2011-01-19
JPWO2006112482A1 (en) 2008-12-11

Similar Documents

Publication Publication Date Title
Carcamo et al. Differential reactivity to IMPDH2 by anti-rods/rings autoantibodies and unresponsiveness to pegylated interferon-alpha/ribavirin therapy in US and Italian HCV patients
MX2009005942A (en) Recombinant antibodies against hepatitis c virus and methods of obtaining and using same.
WO2002089731A3 (en) Agents for treatment of hcv and methods of use
EP0698216B2 (en) Methods of typing hepatitis c virus and reagents for use therein
WO2008031051A3 (en) Clinical diagnosis of hepatic fibrosis using a novel panel of human serum protein biomarkers
DE602006015642D1 (en) HCV REPLICATION INHIBITORS
EP1806363A4 (en) METHOD OF DETECTING HEPATITIS B VIRUS s ANTIGEN
ATE492563T1 (en) COMPLETE HUMAN MONOCLONAL ANTIBODIES AGAINST IL-13
WO2004111082A3 (en) Compound containing polyprotein ns3/ns4 and hcv polypeptide ns5b, expression vectors comprising corresponding nucleic sequences and the therapeutic application thereof
Ahmad et al. HCV and HCC: clinical update and a review of HCC-associated viral mutations in the core gene
WO2009014216A1 (en) Antibody having inhibitory activity on infection with hepatitis c virus (hcv), and use thereof
TW200720656A (en) Prediction of prognosis of liver disease associated with hepatitis c virus infection
WO2007064844A3 (en) Anti-viral griffithsin compounds, compositions, and methods of use
NO20051715L (en) HCV assay
Tanaka et al. Natural history of acute hepatitis C
ATE303597T1 (en) HCV MOSAIC ANTIGEN COMPOSITION
WO2006024020A3 (en) Hcv non-structural protein mutants and uses thereof
WO2005032329A3 (en) Methods and compositions for identifying anti-hcv agents
DK1400589T3 (en) Method for Detecting Prokaryotic DNA
EA200701870A1 (en) PEPTIDE, HAPATITIS C
Karamitros et al. Detection of specific antibodies to HCV‐ARF/CORE+ 1 protein in patients treated with pegylated interferon plus ribavirin
WO2005091199A3 (en) A method for identifying unknown proteins by a two-dimensional step and the use of markers
Gane et al. Antibodies to hepatitis C virus envelope proteins correlate with hepatitis C viraemia after liver transplantation
Fabris et al. Acute hepatitis C: clinical aspects, diagnosis, and outcome of acute HCV infection
ATE552264T1 (en) NEW SURFACE PROTEIN (HBSAG) VARIANT OF HEPATITIS B VIRUS